Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Piramal Enterprises Q1...

    Piramal Enterprises Q1 profit rises 21 percent to Rs 461 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-31T09:00:52+05:30  |  Updated On 14 Aug 2021 11:51 AM IST

    Piramal Enterprises said its total loan book grew 20 per cent year-on-year to Rs 56,605 crore. The housing finance loan book, which constitutes 11 per cent of the company's overall loan book, grew four times to Rs 6,110 crore from the year-ago period.


    Mumbai: Piramal Enterprises on Tuesday reported a net profit of Rs 461 crore in April to June quarter, 21 percent up from Rs 382 crore in the same quarter of previous fiscal.


    The revenue also increased 21 per cent to Rs 3,506 crore in Q1 FY20 from Rs 2,902 crore in Q1 FY19.


    The company said its total loan book grew 20 per cent year-on-year to Rs 56,605 crore. The housing finance loan book, which constitutes 11 per cent of the company's overall loan book, grew four times to Rs 6,110 crore from the year-ago period.


    "We have commenced the new financial year with strong performance across our businesses," said Chairman Ajay Piramal.


    "Despite liquidity tightening in the non-banking financial companies (NBFC) space and overall slowdown across sectors, we have consistently delivered over 20 per cent growth in both revenues and net profits for the last 16 consecutive quarters."


    In the past few months, he said the company has further strengthened its financial services business, on both assets and liabilities side.


    Also Read: Piramal cuts short-term borrowings, reduces dependence on CPs as NBFC crisis lingers


    "We are now committing to bring in Rs 8,000 crore to 10,000 crores of equity in our financial services business during this financial year to leverage the significant growth and consolidation opportunities that are emerging in the NBFC sector," said Piramal.


    In the pharma segment, revenue grew 12 per cent to Rs 1,173 crore while healthcare insights and analytics revenue rose 15 per cent to Rs 319 crore during the quarter.


    In pharma, Piramal Enterprises has 13 end-to-end manufacturing facilities and a large global distribution network to over 100 countries.


    Also Read: Piramal Pharma invests over Rs 69 crore to expand its API capability

    Ajay PiramalNBFCpharmapharma companypharma newsPiramalPiramal enterprisespiramal financial resultspiramal june quarterpiramal Q1Q1Q1 FY20revenue
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok